Develops novel genetic medicines using DNA-directed RNA interference (ddRNAi). Focuses on therapies for chronic and life-threatening human conditions. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 81% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $97.7M in the vault; even if every debt were paid off, $96.9M would remain.
Over the last 12 months, company executives reported 33 buys and 3 sells. Management buying with its own money is usually read as a good sign.
A loss of $37.9M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 19/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 21/100.
On our five-subject report card, BNTC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BNTC is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (45/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.